448 related articles for article (PubMed ID: 26025632)
1. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
[TBL] [Abstract][Full Text] [Related]
2. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban.
Douxfils J; Tamigniau A; Chatelain B; Chatelain C; Wallemacq P; Dogné JM; Mullier F
Thromb Haemost; 2013 Oct; 110(4):723-31. PubMed ID: 23846172
[TBL] [Abstract][Full Text] [Related]
3. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
5. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
6. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
Gosselin R; Grant RP; Adcock DM
Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the use of commercial drug-specific calibrators for determining PT and APTT reagent sensitivity to dabigatran and rivaroxaban.
Gosselin RC; Adcock D; Hawes EM; Francart SJ; Grant RP; Moll S
Thromb Haemost; 2015 Jan; 113(1):77-84. PubMed ID: 25413383
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
Girgis IG; Patel MR; Peters GR; Moore KT; Mahaffey KW; Nessel CC; Halperin JL; Califf RM; Fox KA; Becker RC
J Clin Pharmacol; 2014 Aug; 54(8):917-27. PubMed ID: 24668660
[TBL] [Abstract][Full Text] [Related]
10. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.
Reddy P; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084
[TBL] [Abstract][Full Text] [Related]
11. Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.
Gosselin RC; Adcock Funk DM; Taylor JM; Francart SJ; Hawes EM; Friedman KD; Moll S
Arch Pathol Lab Med; 2014 Dec; 138(12):1680-4. PubMed ID: 25427046
[TBL] [Abstract][Full Text] [Related]
12. Comparison of methods to determine rivaroxaban anti-factor Xa activity.
Rathbun S; Tafur A; Grant R; Esmon N; Mauer K; Marlar RA
Thromb Res; 2015 Feb; 135(2):394-7. PubMed ID: 25476589
[TBL] [Abstract][Full Text] [Related]
13. Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban.
von Horn H; Rasmusson A; Söderblom L; Malmström RE; Antovic J
Int J Lab Hematol; 2022 Feb; 44(1):163-167. PubMed ID: 34523813
[TBL] [Abstract][Full Text] [Related]
14. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin.
Mani H; Rohde G; Stratmann G; Hesse C; Herth N; Schwers S; Perzborn E; Lindhoff-Last E
Thromb Haemost; 2012 Jul; 108(1):191-8. PubMed ID: 22534775
[TBL] [Abstract][Full Text] [Related]
15. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
Molenaar PJ; Dinkelaar J; Leyte A
Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
[TBL] [Abstract][Full Text] [Related]
17. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level?
Gosselin RC; Francart SJ; Hawes EM; Moll S; Dager WE; Adcock DM
Ann Pharmacother; 2015 Jul; 49(7):777-83. PubMed ID: 25855705
[TBL] [Abstract][Full Text] [Related]
18. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
Barrett YC; Wang Z; Frost C; Shenker A
Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
[TBL] [Abstract][Full Text] [Related]
19. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
Samama MM; Contant G; Spiro TE; Perzborn E; Guinet C; Gourmelin Y; Le Flem L; Rohde G; Martinoli JL;
Thromb Haemost; 2012 Feb; 107(2):379-87. PubMed ID: 22187012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
